Document is current

Article History

Received: 13 July 2021

Revised: 14 September 2021

Accepted: 7 October 2021

First Online: 15 January 2022

Declarations

:

: The scientific guarantor of this publication is Jordi Rimola.

: The authors of this manuscript declare relationships with the following companies:.Nunzia Capozzi. received a research grant (BRACCO fellowship) from Bracco Imaging.Elena Ricart has served as a speaker, has received research funding, or has participated in educational and advisory events for MSD, AbbVie, Takeda, Pfizer, Janssen, Frezenius Kabi, Chiesi, and Ferring.Ingrid Ordas has received consulting fees from AbbVie, speaking fees from MSD, Abbvie, Jansen, Takeda, and unrestricted research grants from Faes Pharma and AbbVie.Julian Panés has received research grants from Abbvie MSD and Pfizer and received consulting and/or speaking fees from AbbVie, Abbott, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Celltrion, Genentech-Roche, Gilead, GoodGut, GSK, Janssen, MSD, Nestle, Oppilan, Pfizer, Progenity, Takeda, Theravance, Origo, and TiGenix.Jordi Rimola has received research grants from Abbvie and Genentech and lecture or consultancy fees from Origo Biopharma, Gilead, Takeda, and Janssen; he is on the advisory board of Takeda, TiGenix, Gilead, and Alimentiv.The rest of the authors have no competing interests to disclose.

: Victor Sapena kindly provided statistical advice for this manuscript.

: Written informed consent was obtained from all subjects (patients) in this study.

: Institutional Review Board approval was obtained.

: Some study subjects or cohorts have been previously reported in Capozzi N et al <i>J Crohns Colitis</i>. 2020 Sep 7;14(8):1074-1081

: • prospective• diagnostic or prognostic study• performed at one institution